Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)

BMJ Open (May 2022)

Affiliations

Abhishek Abhishek: Academic Rheumatology, University of Nottingham, Nottingham, UK
Daniel M Altmann: Department of Immunology and Inflammation, Imperial College London, London, UK
Lucy Eldridge: NDORMS, University of Oxford, Oxford, UK
James Bluett: Manchester Academic Health Science Centre, Manchester, UK
Anne Francis: NDORMS, University of Oxford, Oxford, UK
Ines Rombach: Oxford Clinical Trials Unit, Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford Nuffield, Oxford, UK
Duncan Appelbe: NDORMS, University of Oxford, Oxford, UK
Hywel C Williams: Population and Lifespan Health, University of Nottingham, Nottingham, UK
Vicki S Barber: NDORMS, University of Oxford, Oxford, UK
Jonathan Alistair Cook: NDORMS, University of Oxford, Oxford, UK
Ana M Valdes: Academic Rheumatology, University of Nottingham, Nottingham, UK
Laura Coates: NDORMS, University of Oxford, Oxford, UK
Lucy Cureton: NDORMS, University of Oxford, Oxford, UK
Patrick Julier: NDORMS, University of Oxford, Oxford, UK
Nicholas Peckham: NDORMS, University of Oxford, Oxford, UK
Jonathan Nguyen-Van-Tam: Population and Lifespan Health, University of Nottingham, Nottingham, UK
RJ Boyton: Department of Infectious Diseases, Imperial College London, London, UK
Áine McKnight: Blizard Institute, Centre for Genomics and Child Health, Queen Mary University of London, London, UK

Abstract

No abstracts available.